YH 35995
Alternative Names: YH-35995Latest Information Update: 16 Aug 2024
At a glance
- Originator Yuhan
- Developer GC Biopharma; Yuhan
- Class Small molecules
- Mechanism of Action Glucosylceramide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gaucher's disease
- Preclinical Fabry's disease
Most Recent Events
- 30 Jul 2024 Phase-I clinical trials in Gaucher's disease (In volunteers, In adults) in South Korea (PO) (NCT06517914)
- 30 Jul 2024 Preclinical trials in Gaucher's disease in South Korea (PO) prior to July 2024
- 01 Jul 2024 Ministry of Food and Drug Safety approves IND application for YH 35995 in Gaucher's disease